Curocell Inc.
- Biotech or pharma, therapeutic R&D
Curocell's first CD19 pipeline is under regulatory review, expected to launch for commercial sales in Q1 2026. We are looking for a partner interested in our newly-developed a platform technology, called Hyperkine, that enhances T cell functions, which drastically enhances efficacy of CAR-T and TCR-T cells.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}